Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer; ER-positive Breast CancerInterventions: Drug: fulvestrant 500 mg; Drug: Docetaxel (T) 75 mg/m2 (Taxotere); Drug: Trastuzumab (H, 8mg/kg; Drug: Pertuzumab (P, 840 mgSponsor: Western Regional Medical CenterRecruiting - verified January 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Docetaxel | HER2 | Herceptin | Hormonal Therapy | Hormones | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research | Taxotere